Compare DRUG & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRUG | MFA |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.4M | 1.0B |
| IPO Year | 2020 | N/A |
| Metric | DRUG | MFA |
|---|---|---|
| Price | $81.04 | $10.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $114.00 | $10.85 |
| AVG Volume (30 Days) | 90.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.08% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.65 |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.18 | $8.39 |
| 52 Week High | $123.75 | $11.08 |
| Indicator | DRUG | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 58.39 |
| Support Level | $73.97 | $8.91 |
| Resistance Level | $97.75 | $10.21 |
| Average True Range (ATR) | 5.76 | 0.21 |
| MACD | 0.72 | 0.03 |
| Stochastic Oscillator | 53.97 | 76.00 |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.